Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can An Elephant Crack China’s Bamboo Ceiling For Generics?

Executive Summary

Among the many challenges facing foreign generics firms operating in China, dealing with ever-tightening policies and regulations is probably the toughest, and has already forced several multinationals to quit the market. But one Indian joint venture is looking to effectively exploit targeted niche opportunities.

You may also be interested in...

AstraZeneca Divests Antidiabetics To 3SBio In New China Growth Plan

AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.

AstraZeneca Offloads More Mature Drugs To Focus On Core Activities

China Medical System has agreed to pay a total of $500m for selected rights to two mature AstraZeneca PLC cardiovascular products, with the divestments set to provide new growth prospects for the Chinese firm while helping the UK-based multinational focus on innovative products in its second-largest global market.

Merck dissolves Simcere JV amid rapid China changes

Once hailed as the model for global going local in China, a joint venture created merely three years ago between Merck and Simcere has quietly faded into history. Does the move signal that the JV model is not working in China?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts